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ABSTRACT Pseudomonas aeruginosa produces a class C -lactamase (e.g., PDC-3)
that robustly hydrolyzes early generation cephalosporins often at the diffusion limit;
therefore, bacteria possessing these -lactamases are resistant to many -lactam an-
tibiotics. In response to this significant clinical threat, ceftolozane, a 3= aminopyrazo-
lium cephalosporin, was developed. Combined with tazobactam, ceftolozane prom-
ised to be effective against multidrug-resistant P. aeruginosa. Alarmingly, -loop
variants of the PDC -lactamase (V213A, G216R, E221K, E221G, and Y223H) were
identified in ceftolozane/tazobactam-resistant P. aeruginosa clinical isolates. Herein,
we demonstrate that the Escherichia coli strain expressing the E221K variant of
PDC-3 had the highest minimum inhibitory concentrations (MICs) against a panel of
-lactam antibiotics, including ceftolozane and ceftazidime, a cephalosporin that dif-
fers in structure largely in the R2 side chain. The kcat values of the E221K variant for
both substrates were equivalent, whereas the Km for ceftolozane (341 64 M) was
higher than that for ceftazidime (174 20 M). Timed mass spectrometry, thermal
stability, and equilibrium unfolding studies revealed key mechanistic insights. En-
hanced sampling molecular dynamics simulations identified conformational changes
in the E221K variant -loop, where a hidden pocket adjacent to the catalytic site
opens and stabilizes ceftolozane for efficient hydrolysis. Encouragingly, the diazabi-
cyclooctane -lactamase inhibitor avibactam restored susceptibility to ceftolozane
and ceftazidime in cells producing the E221K variant. In addition, a boronic acid
transition state inhibitor, LP-06, lowered the ceftolozane and ceftazidime MICs by
8-fold for the E221K-expressing strain. Understanding these structural changes in
evolutionarily selected variants is critical toward designing effective -lactam/
-lactamase inhibitor therapies for P. aeruginosa infections.
IMPORTANCE The presence of -lactamases (e.g., PDC-3) that have naturally
evolved and acquired the ability to break down -lactam antibiotics (e.g., ceftazi-
dime and ceftolozane) leads to highly resistant and potentially lethal Pseudomonas
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aeruginosa infections. We show that wild-type PDC-3 -lactamase forms an acyl en-
zyme complex with ceftazidime, but it cannot accommodate the structurally similar
ceftolozane that has a longer R2 side chain with increased basicity. A single amino
acid substitution from a glutamate to a lysine at position 221 in PDC-3 (E221K)
causes the tyrosine residue at 223 to adopt a new position poised for efficient hy-
drolysis of both cephalosporins. The importance of the mechanism of action of the
E221K variant, in particular, is underscored by its evolutionary recurrences in multi-
ple bacterial species. Understanding the biochemical and molecular basis for resis-
tance is key to designing effective therapies and developing new -lactam/-
lactamase inhibitor combinations.
KEYWORDS AmpC, PDC-3, antibiotic resistance, beta-lactam, beta-lactamase,
ceftolozane, omega loop
Pseudomonas aeruginosa infections are among the most serious health threats of thiscentury, mostly hospital acquired by immunocompromised patients. P. aeruginosa
is responsible for approximately 51,000 nosocomial infections every year in the United
States (1), and it is one of the top three pathogens of global concern specifically
addressed by the World Health Organization in their guidelines for prevention and
control released late in 2017 (2). In a survey that identified more than 400,000
drug-resistant pathogens collected from 4,515 U.S. hospitals between 2011 and 2014, P.
aeruginosa was the 6th most common nosocomial pathogen, ranking 2nd in ventilator-
associated pneumonia and 3rd in catheter-associated urinary tract infections (3). Par-
ticularly notorious in cystic fibrosis, P. aeruginosa infects 80% of patients by 18 years of
age and results in a 2.6-fold increase in mortality. Alarming levels of resistance are
emerging without compensatory therapies to overcome these infections. P. aeruginosa
produces a chromosomally encoded class C cephalosporinase (Pseudomonas-derived
cephalosporinase, PDC -lactamase) that is often responsible for high-level resistance
to -lactam antibiotics.
Ceftolozane, a “fifth-generation” cephalosporin, is characterized by a 3= aminopyrazo-
lium substitution in the R2 side chain (Fig. 1) and is commercially partnered with tazobac-
tam, a penicillin sulfone and irreversible -lactamase inhibitor. The ceftolozane-tazobactam
combination is active against P. aeruginosa isolates resistant to ceftazidime, carbapenems,
and piperacillin-tazobactam. The advantage of the ceftolozane-tazobactam combination is
that ceftolozane is more stable to PDC hydrolysis than the predecessor -lactam partner of
tazobactam (i.e., piperacillin). Importantly, PDCs are not efficient at hydrolyzing ceftolozane
(4). Unlike tazobactam, ceftolozane inhibits penicillin binding proteins (PBPs), allowing
tazobactam to target other serine -lactamases (e.g., TEM-1) and ESBLs (e.g., CTX-M-15) that
are often present in P. aeruginosa. Alarmingly, resistance to new antibiotics is often reported
before FDA approval (5). Indeed, resistance to ceftolozane-tazobactam has already
emerged and may prove to be a significant clinical threat (6–8).
Among the resistance mechanisms is the evolution of the PDC -lactamase amino
acid variants that often increase catalysis and spectrum of cephalosporin hydrolysis.
Conserved motifs within the AmpC -lactamases, largely the -loop and H10 helix of
the R2 region, seem particularly prone to amino acid substitutions (Fig. 2), insertions,
and deletions that enlarge the active site and accommodate bulkier R1 and R2 groups
of the -lactam, respectively (9, 10). Several PDC -loop variants (PDC-50 V213A;
PDC-74, -75, and -78 G216R; PDC-79 and -86 E221K; PDC-80 E221G; and PDC-85 Y223H)
identified originally in highly drug-resistant P. aeruginosa clinical isolates conferred
resistance to a panel of antibiotics, including ceftazidime and ceftolozane-tazobactam
(11, 12). Herein, we assessed the contribution of these residues (V213, G216, E221, and
Y223) in PDC-3 toward ceftolozane-tazobactam and ceftazidime resistance by perform-
ing a structure-function analysis. In addition, the E221K variant was selected for
in-depth biochemical analysis, revealing robust hydrolysis of ceftolozane as well as
ceftazidime. Importantly, we find that avibactam restored in the strains expressing the
variants susceptibility to ceftolozane and ceftazidime. The boronic acid transition state
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inhibitors (BATSIs) also lowered ceftolozane and ceftazidime MICs of strains harboring
the variants, but the E221K strain maintained modestly high MICs (8 to 16 mg/liter). Our
analysis presented herein provides the first biochemical and molecular dynamics
rationale for enhanced catalytic action against this novel 3= aminopyrazolium cephem.
RESULTS AND DISCUSSION
Single amino acid substitutions in the -loop of PDC-3 enhance resistance
toward ceftolozane and ceftazidime. Previously, five different amino acid substitu-
tions in the -loop (V213A, G216R, E221K, E221G, and Y223H) of the PDC -lactamase
were found to confer enhanced -lactam resistance in clinical isolates (12). Consistent
with this finding, a 5-amino-acid-residue deletion, which included E221 and Y223, and
a 7-amino-acid-residue deletion, including V213 and G216, in PDC -lactamases was
concomitant with increased resistance to ceftazidime-avibactam (13). In response to
selective pressure using ceftolozane-tazobactam, the evolution of the E221K (E247K
including the signal peptide sequence) emerged in a Pseudomonas strain (11). This
particular amino acid substitution arose in SRT-1 of Serratia marcescens as early as 20
years ago (9, 14). To study the role of each of these residues in the mechanism of
resistance and anticipate therapeutic approaches against the variants, we engineered
the V213A, V213G, G216A, G216R, E221A, E221K, E221G, Y223A, and Y223H variants in
FIG 1 Structures of -lactam antibiotics (A) and inhibitors (B) tested in the MIC assays. The R1 side chains of the -lactam antibiotics are shown in red, and
the R2 side chains of the cephalosporins are circled. MIC values from Table 1 are listed for PDC-3 versus E221K.
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PDC-3 for susceptibility determinations, followed by a focused analysis of the E221K
variant’s interactions with ceftolozane and ceftazidime.
The susceptibility of the variants expressed in an isogenic Escherichia coli DH10B
background was tested against a panel of representative cephalosporins, penicillins,
monobactams, and carbapenems (Table 1). Amino acid substitutions in PDC-3 led to
the most significant impact on MICs against ceftolozane, ceftazidime, and aztreonam.
Interestingly, the structures of ceftolozane, ceftazidime, and aztreonam contain the
“bulkiest” and most hydrophilic R1 groups of the compounds tested (Fig. 1A). The
dimethylacetic acid in the R1 group in ceftazidime (also found in ceftolozane and
aztreonam) was specifically associated with antipseudomonal activity (15). The E221K
variant conferred the greatest resistance with an increase of 128-fold in the ceftolozane
MIC and an increase of 32-fold in ceftazidime MIC relative to that of the wild-type strain
(Table 1).
FIG 2 PDC structure (PDB ID 4HEF) showing the -loop (red) at the entrance of the active site and the
H10 helix (blue) of the R2 region that accommodates the R2 side chain of cephalosporins. The active site
serine is shown in stick model representation.
TABLE 1 Susceptibility results of various -lactams against PDC-3 and the variants expressed in the pBC SK (-) vector in E. coli DH10B
cells
Species and straina
MIC value (mg/liter)
Ceftolozane Ceftazidime Cefotaxime Cefepime Ampicillin Piperacillin Aztreonam Imipenem
P. aeruginosa
18SH 8 64 256 128 4,096 512 128 2
PAO1 0.5 1 16 4 2,048 4 4 2
E. coli
DH10B 0.5 0.25 0.06 0.125 4 2 0.125 0.5
DH10B pBC SK 0.5 0.25 0.06 0.06 4 2 0.125 0.25
DH10B pBC SK blaPDC-1 0.5 2 8 0.125 256 16 0.5 0.25
DH10B pBC SK blaPDC-3 0.5 2 8 0.06 256 16 1 0.25
DH10B pBC SK blaPDC-3 V213A 4 32 16 0.125 1,024 64 8 0.5
DH10B pBC SK blaPDC-3 V213G 4 16 16 0.125 1,024 64 8 0.5
DH10B pBC SK blaPDC-3 G216R 8 32 16 0.25 1,024 16 16 0.5
DH10B pBC SK blaPDC-3 G216A 2 16 8 0.125 1,024 64 8 0.5
DH10B pBC SK blaPDC-3 E221K 64 64 4 0.25 256 16 8 0.5
DH10B pBC SK blaPDC-3 E221G 16 32 8 0.125 512 64 4 0.5
DH10B pBC SK blaPDC-3 E221A 2 8 16 0.125 1,024 128 4 0.5
DH10B pBC SK blaPDC-3 Y223H 8 16 8 0.125 512 32 4 0.5
DH10B pBC SK blaPDC-3 Y223A 32 32 16 0.25 256 16 4 0.5
aP. aeruginosa 18SH and P. aeruginosa PAO1 are control strains expressing PDC-3 and PDC-1, respectively.
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Avibactam and boronic acid transition state inhibitors (BATSIs) overcome
resistance to ceftazidime. Several -lactam–-lactamase inhibitor combinations were
selected to test the efficacy of compounds from three different classes of inhibitors
against the strains expressing the variant PDCs. Susceptibility was tested against
tazobactam, a first-generation sulfone inhibitor, combined with piperacillin or ceftolo-
zane; avibactam (16), a diazabicyclooctane (DBO) combined with ceftazidime; and two
boronic acid transition state inhibitors (BATSIs) (a cephalothin analog S02030 [17] and
a ceftazidime analog LP-06 [18]) (see Fig. 1B for structures), each combined with
ceftazidime.
In the piperacillin-tazobactam and ceftolozane-tazobactam combinations, tazobac-
tam led to a 2- to 8-fold attenuation of the variant strain MICs compared to those of the
single antibiotic (Table 2). The E221K variant conferred the greatest resistance to
ceftolozane and ceftazidime. Susceptibility to ceftolozane and ceftazidime was sub-
stantially restored when these oxyimino cephalosporins were paired with avibactam
(MICs  1 mg/liter). In other studies, select  loop variants were associated with
resistance to these clinically available combination therapies (12, 13). Therefore, we
extended the study to include testing of BATSI inhibitors, which are chemically distinct
from tazobactam and avibactam (Fig. 1). Interestingly, the LP-06 and S02030 BATSIs
lowered the MIC values of ceftolozane and ceftazidime for all variant strains, but the
strain expressing E221K maintained the highest MICs (8 to 16 mg/liter) (Table 2). LP-06
lowered the MICs more effectively than S02030 did, particularly for the Y223A variant
strain. Further, LP-06 was as potent as avibactam in all variant strains except the strain
harboring the E221K variant.
Protein expression of PDC-3 and the E221K variant in the cell is lower than the
other variants. To determine whether the elevated MIC values for the E221K variant
strain were due to a higher expression level of the -lactamase protein in the cell, we
developed and used an anti-PDC-3 antibody to perform immunoblotting on the strains
harboring PDC-3 and the variants (Fig. 3). E. coli strains variably expressed each PDC-3
variant. On the basis of the epitope mapping of PDC-3 using a SPOT-synthesis tech-
nique, we posit that changes in the binding of the anti-PDC-3 antibody to the newly
introduced amino acids in the variants does not account for differences in intensities in
the immunoblot; the epitopes do not encompass the V213, G216, E221, and Y223
amino acid residues (Fig. S1). Strikingly, the amount of the E221K variant most closely
TABLE 2 Susceptibility results of various -lactams compared to -lactams in combination with -lactamase inhibitors against PDC-3 and
variants expressed in the pBC SK (-) vector in E. coli DH10B cells
Species and straina
MIC value (mg/liter)b
PIP
PIP-
TAZ TOL
TOL-
TAZ
TOL-
AVI
TOL-
LP06
TOL-
S02030 CAZ
CAZ-
AVI
CAZ-
LP06
CAZ-
S02030
P. aeruginosa
18SH 512 256 8 8 8 8 8 64 2 32 64
PAO1 4 4 0.5 0.5 0.5 0.5 0.5 1 1 0.5 1
E. coli
DH10B 2 2 0.5 0.25 0.5 0.5 0.25 0.25 0.25 0.25 0.25
DH10B pBC SK 2 2 0.5 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25
DH10B pBC SK blaPDC-1 16 8 0.5 0.5 0.5 0.25 0.25 2 0.25 0.25 0.25
DH10B pBC SK blaPDC-3 16 4 0.5 0.5 0.5 0.25 0.25 2 0.25 0.25 0.25
DH10B pBC SK blaPDC-3 V213A 64 16 4 2 0.5 0.25 0.25 32 0.25 0.25 1
DH10B pBC SK blaPDC-3 V213G 64 8 4 2 0.5 0.25 0.25 16 0.25 0.25 1
DH10B pBC SK blaPDC-3 G216R 16 8 8 4 0.25 0.5 0.5 32 0.25 0.25 1
DH10B pBC SK blaPDC-3 G216 64 8 2 2 0.25 0.25 0.25 16 0.25 0.25 0.25
DH10B pBC SK blaPDC-3 E221K 16 8 64 8 1 8 8 64 0.5 8 16
DH10B pBC SK blaPDC-3 E221G 64 16 16 4 0.5 1 2 32 0.5 0.5 1
DH10B pBC SK blaPDC-3 E221 128 16 2 2 0.5 0.5 0.25 8 0.25 0.25 0.25
DH10B pBC SK blaPDC-3 Y223H 32 4 8 1 0.25 0.5 0.5 16 0.5 0.5 2
DH10B pBC SK blaPDC-3 Y223A 32 4 32 4 1 2 8 32 0.5 0.5 8
aP. aeruginosa 18SH and P. aeruginosa PAO1 are control strains expressing PDC-3 and PDC-1, respectively.
bPIP, piperacillin; TAZ, tazobactam; TOL, ceftolozane; AVI, avibactam; CAZ, ceftazidime.
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mimicked the low expression of wild-type PDC-3 -lactamase. Further, the E221K
variant was detected at the lowest level of expression relative to the other variants, a
remarkable observation when considering that the E221K variant confers the highest
level of resistance against the tested antibiotics (Tables 1 and 2). Supporting this
observation, previous studies suggested that overexpression of PDC proteins alone is
not always sufficient to account for such robust resistance (11, 12, 19). To further
explore the mechanisms of resistance, we tested the -lactam kinetic characteristics of
the E221K variant.
Mechanisms of catalysis: PDC-3 -lactamase fails to establish an acyl complex
with ceftolozane but forms a prolonged acyl-complex with ceftazidime. The
wild-type PDC-3 hydrolyzed ceftolozane and ceftazidime albeit poorly (Fig. 4A and B),
consistent with the MIC results. As expected, PDC-3 demonstrated a lower Km toward
ceftazidime compared to ceftolozane. Using a competitive inhibition assay with nitro-
cefin as the reporter substrate, the Ki app of ceftolozane (1.3 mM) was determined to be
60-fold higher than that of ceftazidime (22 M) with PDC-3. Thus, PDC-3 interacts
favorably with ceftazidime compared to ceftolozane, yet is not hydrolyzed (Fig. 4B).
To further investigate the catalytic mechanism, we performed timed mass spec-
trometry. Two isoforms of PDC-3 and E221K were expressed and purified due to the
presence of additional methionine at the N terminus (20) (Fig. 5). Using a 1:1 molar ratio
of enzyme to substrate, timed mass spectrometry analysis captured the binding of
PDC-3 to ceftazidime, but not to ceftolozane (Fig. 5 and Table 3). The observed masses
reflect cephalosporins without the R2 group (circled in Fig. 2). Cephalosporins that
demonstrate efficient R2 elimination typically have more reactive -lactam rings and
enhanced activity (21). Elimination of the R2 group from cephalosporins results from
electron transfer upon binding to -lactamases and was previously shown for ceftazi-
dime and ceftolozane among other cephalosporins (21–25). An acyl-complex with
ceftolozane or ceftazidime was not detected with the E221K variant, but ceftazidime
without its R2 group was captured in complex with PDC-3 (Fig. 5).
As indicated by a lower Km, nearly 60-fold-lower apparent inhibition constant
(1.3 mM ceftolozane Ki app versus 22 M ceftazidime Ki app), and the ability to capture
the ceftazidime acylated PDC-3 complex, ceftazidime must be able to occupy the active
site of PDC-3 despite overall hydrolytic deficiency. Contrary to ceftazidime, the failure
of PDC-3 to hydrolyze ceftolozane is more likely due to the inability of the PDC-3 active
site to accommodate the more basic and extended 3= aminopyrazolium-containing R2
side chain of ceftolozane (Fig. 2) and form an acyl-complex (see “Molecular modeling”
below). We also have not ruled out product inhibition as a mechanism. Modifications
of the 3-aminopyrazolium side chains during the structural derivation of ceftolozane
correlated with stability to class C -lactamases, likely due to steric hindrance (26). The
mechanisms of these third-generation cephalosporins contrast with that of the fourth-
FIG 3 Immunoblots of E. coli DH10B whole-cell lysates of PDC-3 and variants expressed in the pBC SK
(-) vector. The P. aeruginosa 18SH clinical isolate and purified PDC-3 -lactamase are used as positive
controls. An anti-DnaK antibody was used as a loading control.
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generation cephalosporin cefepime, which has a zwitterionic quaternary amine as the
R2 group that decreases affinity for -lactamases (Fig. 1) (27) and effectively overcomes
resistance conferred by the PDC variants in E. coli (Table 1).
Acquisition of hydrolytic efficiency: the E221K variant demonstrates robust
hydrolysis of ceftolozane and ceftazidime. Consistent with increased resistance of
the variants compared to PDC-3 (Table 1 and 2), the E221K variant acquired an ability
to efficiently hydrolyze ceftolozane (Fig. 4A) and ceftazidime (Fig. 4B). Km for the E221K
variant for ceftazidime is 174 20 M (Table 4), considerably higher than previously
reported values of 35 M (28) and 51.7 2.1 M (20) for PDC-3. Turnover (kcat) for
E221K for ceftazidime is 9 1 s1 (Table 5), substantially greater than the 0.02 s1 (28)
and 0.002 s1 (4) values reported for PDC-3. Catalytic efficiency (kcat/Km) for E221K
(5.2 0.8 102M1 s1) is notably higher for ceftazidime than the reported values
of PDC-3; 0.0006 M1 s1 (28) and 0.00033 M1 s1 (4).
E221K exhibited a higher Km value for ceftolozane (341 64M) than for ceftazidime
(174 20M) (Table 4). The other kinetic parameters were similar for E221K between the
substrates: ceftolozane (kcat of 10 1 s1 and kcat/Km of 0.029 0.006M1 s1) and
ceftazidime (kcat of 9 1 s1 and kcat/Km of 0.052 0.008M1 s1) (Table 4). The efficient
hydrolysis of ceftolozane and ceftazidime by E221K is consistent with the inability to
capture the acyl-E221K complexes by timed mass spectrometry due to the rapidity of the
reaction (Fig. 5).
The BATSIs are potent inhibitors of PDC-3 and the E221K variant. The steady-
state inhibitory kinetics of the BATSIs were assessed using nitrocefin as a reporter
substrate (nitrocefin Km for PDC-3 (20 2 M) and E221K (17 3 M)). S02030, the
cephalothin analog, and LP-06, the ceftazidime analog, inhibit PDC-3 and the E221K
FIG 4 Hydrolysis of ceftolozane (A) and ceftazidime (B) by PDC-3 and the E221K variant. Ceftolozane
(100 M) was tested with 1 M enzyme (PDC-3 or E221K). Ceftazidime (300 M) was assayed with
100 nM enzyme (PDC-3 or E221K).
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variant at nanomolar concentrations. LP-06 and S02030 inhibited PDC-3 more effi-
ciently than E221K did (Table 5). Comparison between the two inhibitors suggests that
LP-06 has superior inhibitory activity compared to S02030 for both PDC-3 and E221K
(Table 5).
BATSI inhibitors increase the thermodynamic stability of PDC-3 and E221K. The
thermodynamic stability of PDC-3 and E221K was determined from equilibrium unfold-
ing curves (Fig. 6). Thermal denaturation revealed that the E221K variant is less stable
compared to PDC-3 (Tm of 45°C and 52°C, respectively), with a ΔΔGu  2.32 0.2
Kcal/mol loss in stability (Fig. 6). Binding of the S02030 BATSI inhibitor to either PDC-3
or the E221K variant increased the stability (6°C increase for PDC-3 and 3 to 4°C increase
for the variant) (Fig. 6A). Similarly, the LP-06 BATSI stabilized both PDC-3 (6°C increase)
and E221K (5°C increase) (Fig. 6B), as previously observed for other BATSIs with SHV-1,
ADC-7, and AmpC (29–32). Increased stability between the inhibitors and the
FIG 5 Electrospray ionization mass spectrometry (ESI-MS) of pure PDC-3 and the E221K variant incubated with ceftolozane (TOL) (MW,
666 Da; MW without R2 group, 471 Da) or ceftazidime (CAZ) (MW without R2 group, 468 Da) for 15 s or 15 min at a 1:1 molar ratio.
Methionine (Met) has a molecular weight of 131 Da. Mass accuracy is 5 Da.
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-lactamases is indicative of higher energy for noncovalent interaction in the covalent
acyl complexes compared to the -lactamase alone (31). Thus, increased stability of
PDC-3 with the BATSIs, reflective of increased interactions and the formation of
inhibitory complexes, would predict the lower ceftazidime-BATSI MICs compared to
ceftazidime alone MICs in Table 2.
Notably, the thermal denaturation profiles showed a further distinction between
PDC-3 and the E221K variant. The transition where the inhibitor-bound PDC-3 began to
TABLE 3 Predicted masses of PDC-3 and the E221K variant -lactamases with and
without the addition of ceftazidime and ceftolozanea
aPredicted masses of PDC-3 and the E221K variant -lactamases with and without the addition of
ceftazidime (CAZ) and ceftolozane (TOL). The R2 group is eliminated from the cephalosporin upon binding
to -lactamase. The additional Met residue was a result of cloning and does not impact -lactamase
activity.
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unfold occurred at 4°C, higher than for PDC-3 alone, shifting the curve for the
inhibitor-bound PDC-3 to the right (Fig. 6). After the initial transition, PDC-3 unfolded
at a similar rate with and without inhibitor as reflected by a uniform difference (	4°C)
between the two melting curves (Fig. 6). Conversely, the E221K variant started to unfold
at the same temperature regardless of whether it was bound by inhibitor, but the
steeper slope of E221K alone suggested a higher rate of unfolding in the absence of
inhibitor.
The lower unfolding rate of inhibitor-bound E221K compared to inhibitor-bound
PDC-3 could be due to additional interactions between the LP-06 and E221K as
suggested by our molecular modeling (Fig. 7). The boronic and carboxylic acids of LP-06
interact with residue S319 in PDC-3. In the E221K variant, the interaction between the
boronic acid and S319 is maintained, but the carboxylic acid-S319 bond is lost. Further,
LP-06 forms new bonds with the S319, N320, Q120, and Y151 residues of E221K. To
further explore the structural changes in the E221K compared to PDC-3, we employed
molecular modeling and molecular dynamic simulations using ceftolozane as the
substrate.
Molecular dynamic simulations reveal conformational changes in the E221K
variant that accommodate binding of ceftolozane. Classical atomistic molecular
dynamics (MD) and well-tempered metadynamics simulations (WT-MetaD) were carried
out to enhance conformational sampling of PDC-3 and variants (Fig. 8). Free energy
surface (FES) plots were calculated for each system, highlighting basins of lowest
energy states as shown in the red wells in Fig. 8 (e.g., e1 and k1), wherein each basin
corresponds to an ensemble of conformations of the protein. Conformations of PDC-3
and the variants were extracted from the free energy minima and superimposed onto
the crystal structure (PDB ID, 4HEF, yellow).
The E221K variant adopts conformations in the free-energy landscape that are not
accessible by PDC-3 (E221) (Fig. 8). Generally, the E221 variants are able to explore the
conformation in k1, a1, and g1 energy basins that are similar to the conformation in the
wild-type (e1) (Fig. 8B to D). However, other energy basins such as k3 are observed
exclusively by the E221K variant (Fig. 8B). Moreover, the clustered (representative)
structures illustrate that the conformation adopted by the -loop in particular is
distinct from that of the crystal structure. Consistent with the conformational changes,
the hydrogen bonding patterns are altered in the E221 variants. In PDC-3, the side chain
of E221 forms hydrogen bonds with K67, but these bonds are disrupted in the E221K,
E221A, and E221G variants.
In the Michaelis-Menten complex, rotation of the Y223 residue in E221K
supports binding of ceftolozane. Enhanced sampling simulations identified confor-
mations in the E221K variant, which were not found in the wild type. The conformations
TABLE 4 Steady-state kinetics of the E221K variant with ceftazidime and ceftolozanea
Parameter E221K-ceftolozane E221K-ceftazidime
Vmax (M/s) 1.0  0.1 0.9  0.1
Km (M) 341  64 174  20
kcat (s1) 10  1 9  1
kcat/Km (M1 s1) (2.9  0.6) 102 (5.2  0.8) 102
aPDC-3 hydrolysis of ceftolozane and ceftazidime was negligible.
TABLE 5 Inhibition kinetics of PDC-3 and the E221K variant with the BATSI compoundsa
-Lactamase (IC50)
IC50 (nM) for -lactamase with:
LP-06 S02030
PDC-3 (1.5 nM) 9  1 62  2
E221K (20 nM) 342  20 769  30
aInhibition kinetics of PDC-3 and the E221K variant with the BATSI compound LP-06 or S02030, determined
after a 5-min preincubation with LP-06 or S02030 with cell lysate. Nitrocefin was used as the reporter
substrate.
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identified for E221K indicated a rotation of the Y223 side chain. The Y223 residue in
PDC-3 adopts several positions within the same plane (Fig. 9A), whereas in the E221K
variant, Y223 flips into a perpendicular plane, opening a hidden cavity adjacent to the
catalytic site (Fig. 9B), which is occluded by Y223 in the crystalline form of PDC-3. These
data are supported by previous work in E. coli class C cephalosporinases, where a steric
clash between the tyrosine ring and R1 cephalosporin side chains was concluded from
the crystal structure of AmpC with a glycine substitution in the Y223-equivalent residue
(Y221G) of PDC (33). Increased flexibility in the -loop was also observed in the crystal
structure of the E221K analog of AmpC of E. coli (E219K) (33). This newly adopted
conformation and change in the architecture of the -loop facilitate the formation of
Michaelis-Menten complex between the E221K variant and ceftolozane. The amin-
opyrazole group in the R2 side chain of ceftolozane seems to be the specific moiety
responsible for its inability to bind to PDC-3. These data are supported by measurable
steady-state kinetic parameters (e.g., Km of 341 64 M) (Table 4) and elevated MICs
(ceftolozane MIC PDC-3 of 0.5 M ¡ E221K 64 M) (Table 2).
FIG 6 Thermal denaturation of PDC-3 and E221K with S02030 (A) or LP-06 BATSI (B) inhibitors, expressed
as a ratio of folded protein to unfolded protein.
FIG 7 Molecular modeling of PDC-3 (A) and the E221K variant (B) bound to LP-06, a ceftazidime-like BATSI. LP-06
is represented as a stick figure with carbon in pink, sulfur in yellow, nitrogen in purple, oxygen in red, and boron
in rose color.
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In the acyl-complex, ceftolozane interacts favorably with the E221K variant,
but it is unable to interact productively with PDC-3. Connolly representations depict
overt changes in electrostatic potential when the E221 residue is changed to a lysine
(Fig. 9C and D). Y223 and E221 are located in the center of the green circle in Fig. 9C
and D. The calculated potential of PDC-3 is 1318 kT compared to the potential of the
FIG 8 Conformational free energy surface (FES) reconstructed from metadynamics simulations of PDC-3
(A) and the E221 variants E221A (B), E221K (C), and E221G (D). Representative conformations corre-
sponding to each energy basin (e.g., e1, e2) are superimposed onto the crystal structure, shown on the
right. The -loop of the crystal structure of wild-type E221 (yellow) and the simulated result of the
structure (red) are highlighted. The amino acid of interest (wild-type E221 or the A, K, and G substitutions)
in each panel is visualized in red and blue using a Corey-Pauling-Koltun (CPK) representation.
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E221K variant at 1,304 kT (delta 13.4 kT). Docking of ceftolozane into the active site
of the E221K variant illustrates that ceftolozane forms hydrogen bonds with residues
S64, N153, K316, S319, K67, N344, and N321 (Fig. 9E). In addition, ceftolozane forms
steric interactions with Y223, S319, and N347.
An accurate acyl-enzyme model of ceftolozane and PDC-3 was not possible because
ceftolozane is too bulky to readily position into the active site of PDC-3. Ceftolozane
sterically clashes with the active site residues at the entrance of PDC-3 (positions 120
to 125) and -loop residues (positions 209 to 217), giving rise to a multitude of
unproductive conformations. To better understand the effect of the single amino acid
substitutions at an atomic level, we analyzed the dynamics and energetics of the PDC-3
and the E221K variant.
Enhanced sampling simulations reveal that the ion-pair interactions made between
D191 and K226 help anchor the -loop in a conformation that allows the side chain of
Y223 to change its orientation to point away from the catalytic site. This in turn reveals
a hidden pocket, which can accommodate the tail of ceftolozane. The increase in
FIG 9 Representative conformations of PDC-3 (A) and E221K (B) corresponding to individual energetic basins
extracted from metadynamics simulations which show the conformational change of Y223. Connolly representa-
tion of PDC-3 (C) and the E221K variant (D) based on the calculated electrostatic potential showing significant
electrostatic changes introduced by the E221K substitution. (E) Molecular modeling of E221K and ceftolozane as
acyl enzyme complex. Ceftolozane is represented as a stick figure with carbon in blue, sulfur in yellow, nitrogen
in purple, and oxygen in red.
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conformational flexibility and expansion of the active site entrance likely explains why
the E221K variant acquires the ability to accommodate ceftolozane in its active site and
hydrolyze both ceftolozane and ceftazidime, despite the difference in size (Fig. 2).
Conclusions. Our previous findings showed that amino acid substitutions in the
C3/C4 -lactam carboxylate recognition region of PDC-3 increase or maintain antibiotic
susceptibility (20). The emergence of mutations in AmpC -lactamases as a mechanism
of resistance to ceftolozane has gone largely unexplored (from a biochemical and
mechanistic standpoint) with an underestimated occurrence of 1.5% resistance to
-lactams (12), but it has attracted more attention in recent years (11, 12, 34, 35). Here,
we focused on clinically important amino acid substitutions in the -loop of PDC-3 and
how they contribute to the resistance profile. While PDC-3 is our primary focus in this
study, the vital impact that the residues in the -loop have on structural integrity and
catalytic activity is not limited to PDC-3, or even class C, -lactamases (22, 36–41).
Herein, we first showed that the hydrolysis of ceftazidime by the wild-type -lactamase
PDC-3 is deficient despite the ability of ceftazidime to dwell in the active site of PDC-3.
To our knowledge, this insight has not been significantly appreciated. A single amino
acid substitution, E221K, in PDC-3 enabled the -lactamase to acquire increased
hydrolytic activity and induced multiple conformations of the variant, identified by
enhanced sampling simulations. This particular substitution has already evolved in the
clinic in multiple species (12, 14), and therefore may be evolutionarily favored to
emerge in additional drug-resistant pathogens. The potential severity of the variants in
the clinic is exacerbated by increased resistance to aztreonam as well as ceftolozane
and ceftazidime. Further, employment of molecular dynamic simulations and other
biophysical methods to capture dynamic interactions are useful for elucidating protein
structure-function relationships.
The gain of function observed in enhanced catalysis is not obtained without a
sacrifice. The E221K protein acquires hydrolytic activity at the detriment of conforma-
tional restraints that destabilize the infrastructure of the protein, which is partially
restored by binding to inhibitors. Importantly, despite the E221K variant’s enhanced
cephalosporinase activity, avibactam and the LP-06 BATSI effectively lowered ceftolo-
zane and ceftazidime MIC values of the E221K strain. BATSIs and DBOs may be able to
serve as partners for novel combinational therapies against P. aeruginosa infections.
More importantly, by differing significantly from the ceftolozane-tazobactam mecha-
nism of inactivation, these “second-generation” -lactamase inhibitors offer promise
against this significant threat to our armamentarium (42).
MATERIALS AND METHODS
Critical reagents and strains. Ceftazidime was procured from Sigma-Aldrich (catalog no. C3809) and
Research Products International (catalog no. 33527) and used interchangeably throughout the experi-
mentation. Merck & Co., Inc. (Kenilworth, NJ, USA) provided ceftolozane powder. Avibactam was
purchased from Advanced ChemBlocks (catalog no. R16073). Piperacillin (catalog no. P8396), cefotaxime
(catalog no. C7912), and chloramphenicol (catalog no. R4405) were purchased from Sigma-Aldrich.
Imipenem was obtained from USP (catalog no. 1337809) and from the commercial source. Tazobactam
(catalog no. 15141) and aztreonam (catalog no. 15151) were purchased from Chem-Impex International.
Ceftolozane-tazobactam, cefepime, and meropenem were obtained from their commercial sources.
Nitrocefin (catalog no. BR0063G) was purchased from Oxoid. The LP-06 and S02030 BATSIs were
synthesized as previously described (43, 44). See Drawz et al. (20) for a discussion on the P. aeruginosa
control strains (18SH AmpC for PDC-3 and PAO1 for PDC-1).
Expression and purification of PDC-3 and E221K. PDC-3 -lactamase was cloned into the pER24a
(
) vector as previously described (20). PDC-3 -lactamase was purified from E. coli Origami 2 DE3
(Novagen) cells carrying the pET24a (
) blaPDC-3 or pET24a (
) blaPDC-3-E221K plasmid that produces the
corresponding PDC-3 protein without its signal peptide, similar to the previously described protocol (20,
45). Cells were grown in 500 ml super optimal broth (SOB) at 37°C to an optical density at 600 nm (OD600)
of approximately 0.6 to 0.8 and induced with 1 mM isopropyl--D-1-thiogalactopyranoside (IPTG) for a
minimum of two and a half hours to express the -lactamase. The cell pellets were generated by
centrifugation and frozen at 20°C for 12 h prior to a 40-min lysis in 50 mM Tris-HCl buffer (pH 7.4)
containing 40 mg/ml lysozyme, 0.1 mM magnesium sulfate, 250 U benzonase nuclease, and 1 mM
ethylenediaminetetraacetic acid (EDTA). The supernatant was further purified using a HiTrap SP Sephar-
ose cation exchange column (GE Healthcare Life Sciences) and 25 mM Tris-HCl (pH 7.4). Protein was
eluted from the column using 25 mM Tris-HCl (pH 7.4) and 0.5 M NaCl. If needed, the sample of protein
was concentrated using centrifugal filter units with a 10,000-dalton-molecular-weight cutoff (Millipore).
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The protein was subjected to gel filtration using a Sepahadex (75 prep grade) HiLoad 16/600 column in
10 mM phosphate-buffered saline (PBS), pH 7.4. The final sample of protein was concentrated using
centrifugal filter units with a 10,000-dalton-molecular-weight cutoff (Millipore). The purity of the proteins
was assessed by quadrupole time of flight (Q-TOF) mass spectrometry (see below). Protein concentra-
tions were determined by measuring absorbance at a wavelength of 280 nm (280) and using the
protein’s extinction coefficient (Δ  54,320 M1 cm1) obtained using the ProtParam tool at ExPASy
Bioinformatics Resource Portal.
Purification of anti-PDC-3 antibody. For the SPOTS membrane, the PDC-3 protein (3 mg of protein
in 10 mM phosphate-buffered saline [PBS], pH 7.4) was provided to New England Peptide (Gardner, MA)
for polyclonal antibody production in a rabbit. The serum was purified using a protein G column to
obtain polyclonal immunoglobulin antibodies against PDC-3. Briefly, 3 ml of rabbit serum was added to
a binding buffer composed of 20 mM NaH2PO4 (pH 7.0) and added to a 5-ml HiTrap Protein G HP column
(GE Healthcare, Piscataway, NJ) with a flow rate of 0.5 ml/min. The bound anti-PDC-3 was eluted from the
column using 0.1 M glycine-HCl (pH 2.7) and neutralized with 1 M Tris-HCl (pH 9.0). The antibody
concentration was quantified using spectrophotometric determination at 280 nm and stored at 20°C.
Epitope mapping (SPOTs membrane). An epitope map of the PDC-3 -lactamase was created using
SPOT synthesis on a cellulose membrane by JPT Peptide Technologies GmbH (Berlin, Germany) as
previously described (46, 47). Briefly, peptides with an acetylated N terminus were covalently bound to
a Whatman 50 cellulose membrane by the C terminus. The membrane was incubated in methanol for
5 min, washed three times with Tris-buffered saline (TBS) for 10 min each time, and blocked with 5% milk
in TBS overnight. The following day, the membrane was washed four times with TBS for 4 min each time.
Primary antibody was added at 1 mg/liter in 5% milk in TBS for 3 h. Blots were washed four times with
TBS-Tween (TBS-T) for 10 min each time before incubation with a secondary antibody (protein G-HRP)
diluted 1:5,000 for 1 h. Blots were washed four times with TBS-T for 10 min each time and processed with
the ECL Prime kit (Amersham/GE Healthcare, Piscataway, NJ).
Immunoblotting of PDC-3 -lactamase. Log-phase protein expression was determined as previ-
ously described (45). One milliliter of bacteria grown to an OD600 of 0.6 to 0.8 in lysogeny broth (LB) in
20 g/liter chloramphenicol was pelleted and resuspended in sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) buffer. Each sample (10 l) was separated by SDS-PAGE. Proteins were
transferred to polyvinylidene fluoride membranes for 2 h at 80 V. The membranes were blocked
overnight in 5% milk in Tris-buffered saline (TBS) solution, followed by a 1- to 3-h incubation with a
0.1 mg/liter primary PDC-3 (anti-18SH, 42) rabbit polyclonal antibody and an anti-DnaK rabbit polyclonal
antibody (Stressgene, San Diego, CA) diluted 1:15,000 (loading control) in 5% milk/TBS and finally
incubated with the protein G-HRP conjugate at a 1:10,000 dilution for 1 h in 5% milk/TBS. An ECL Prime
Western blot exposure kit from Amersham was used to visualize the blot on the Fotodyne imager.
Susceptibility testing. Variant genes were synthesized into the pBC SK (-) vector by Celtek Biosci-
ence (Franklin, TN). Mueller-Hinton (MH) agar-dilution MIC measurements were performed against
isogenic transformants producing PDC-3 and nine variants of PDC-3 in pBC SK (-) according to the Clinical
and Laboratory Standards Institute (CLSI) guidelines as previously described (39, 48). Avibactam, LP-06,
and S02030 were tested at a constant 4 g/ml in combination with various concentrations of ceftazi-
dime. Piperacillin-tazobactam was maintained at a ratio of 8 piperacillin to 1 tazobactam. Ceftolozane-
tazobactam was maintained at a ratio of 2 ceftolozane to 1 tazobactam. The MICs are reported as the
concentrations at which bacterial growth was no longer observed. All MIC measurements were per-
formed at least three times.
Steady-state kinetic and inhibitor analysis. Steady-state kinetic and inhibitor parameters were
determined by using an Agilent 8453 diode array spectrophotometer at room temperature as previously
described (20, 43, 49). Each assay was performed in 10 mM phosphate-buffered saline (PBS) at pH 7.4 at
room temperature (RT  	25°C) in a quartz cuvette with a 1-cm path length. Measurements were
obtained using ceftolozane and ceftazidime. The kinetic parameters, Vmax and Km, were obtained with a
nonlinear least-squares fit of the data (Henri Michaelis-Menten, equation 1) using Origin 7.5VR (OriginLab,
Northampton, MA).
v
Vmax S
Km	 S
(1)
For the reversible boronic acid inhibitors, measurements were obtained for E221K and PDC-3 using
nitrocefin (Δ482 17,400 M1 cm1) as a reporter substrate. Because of the time-dependent inhibition
observed previously with some of the chiral boronates (43), the BATSIs were preincubated with enzyme
for 5 min in phosphate-buffered saline before initiation of the reaction with the addition of substrate. The
initial velocity (0 to 10 s) was measured in the presence of a constant concentration of enzyme (1.5 nM
PDC-3 and 20 nM E221K) and increasing concentrations of the inhibitors against the fixed concentration
(100 M) of the indicator substrate, nitrocefin. The IC50 is the concentration of inhibitor that reduces the
velocity by 50%. IC50 values were determined by fitting the initial velocity (v0) measurements to equation 2.
v0
VmaxS
Km1	 IIC50	 S
(2)
For competitive inhibition assays used to determine Ki app, 150 M nitrocefin was used as the reporter
substrate with increasing concentrations of ceftazidime or ceftolozane. Initial velocities were plotted
against concentrations of ceftazidime or ceftolozane. Ki app obs were determined by dividing the slope by
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the y intercept. Ki app was calculated by correcting Ki app obs for nitrocefin affinity and concentration
(equation 3).
Ki app Ki app obs ⁄ [1	 ([NCF] ⁄ Km NCF) (3)
Electrospray ionization mass spectrometry (ESI-MS). Five micrograms of -lactamase (PDC-3,
E221K) was incubated with the substrate at a 1:1 molar ratio (PDC-3 and ceftazidime or ceftolozane) in
10 mM PBS at pH 7.4 for a total reaction volume of 20 l for the times indicated in the figures. Reactions
were quenched with 10 l acetonitrile and added to 1 ml of 0.1% formic acid in water. Samples were
analyzed using Q-TOF Waters Synapt-G2-Si and Waters Acquity UPLC BEH C18 1.7-m column (2.1 by
50 mm). MassLynx V4.1 was used to deconvolute protein peaks. The tune settings for each data run were
as follows: capillary voltage at 3.5 kV, sampling cone at 35, source offset at 35, source temperature of
100°C, desolvation temperature of 500°C, cone gas at 100 liters/h, desolvation gas at 800 liters/h, and
nebulizer bar at 6.0. Mobile phase A was 0.1% formic acid in water. Mobile phase B was 0.1% formic acid
in acetonitrile. The mass accuracy of this system is 5 Da.
Thermal denaturation. Circular dichroism (CD) experiments were carried out in a Jasco (Easton, MD)
J-815 spectrometer with a Peltier effect temperature controller. Quartz cells with a 0.1-cm path length
were used for all experiments.
PDC-3 enzyme and the E221K variant (10 M) with or without S02030 or LP-06 (200 M) were
monitored for thermal denaturation by CD at 215 and 221 between 20 and 80°C with a heating rate of
2°C/min. Two-state behavior was indicated by identical curves at each wavelength. Raw equilibrium
denaturation data were normalized to the fraction of denatured protein (fU). With the assumption of a
reversible two-state transition (N ↔ U), equilibrium constants (Keq) at any given temperature were
calculated, as previously described (32), using equation 4
Keq fU ⁄ (1
 fU) (4)
With the assumption that enthalpy and entropy changes do not vary with the temperature
(ΔCp constant), from the Gibbs free energy and van’t Hoff equation (ΔG ΔHVH TΔSRTlnKeq) (50)
the ΔHVH was determined as the slope from equation 5 (R is the gas constant). The melting temperature
Tm was determined at the midpoint of equilibrium folding (T Tm) when ΔG 0.
ln Keq 1 ⁄ T (
H ⁄ R)	S ⁄ R (5)
The free energy of unfolding was determined as previously described using the equation
ΔΔGu ΔTmΔSuPDC-3 (Schellman), where ΔSuPDC-3  0.326 0.02 Kcal mol1 K1.
Molecular modeling. (i) Docking. Structural representations of PDC-3 and the E221K variant of
KPC-2 -lactamase were generated using the crystal coordinates of P. aeruginosa AmpC (PDC-1) (PDB ID
4HEF) and Discovery Studio 2016 (DS 2016) (Dassault Systèmes BIOVIA; Discovery Studio Modeling
Environment, San Diego, CA) molecular modeling software as previously described (37, 51). The T79A
substitution (T79A substitution corresponds to T105A in 4HEF because of the 26-amino-acid signal
peptide) was incorporated into the PDC-1 -lactamase structure to obtain the PDC-3 -lactamase
structure.
(ii) Acyl complex. The PDC-3 -lactamase structure and the variant model were solvated and
minimized to an RMS of 0.03 Å using the conjugate gradient method. The intact and acylated ceftolozane
were constructed using the Fragment Builder tools and minimized using a Standard Dynamics Cascade
protocol of DS. Both molecules were docked automatically into the active site of the PDC-3 and E221K
variant using CDOCKER module of DS. To obtain acyl-enzyme complexes, the most favorable conforma-
tion demonstrating anticipated active site contacts was chosen, and the complex was further minimized.
The spatial distribution of the electrostatic potential and the potential of PDC-3 and E221K variant atoms
were calculated using the DelPhi program with Debye-Huckel boundary condition approximation. The
DelPhi calculation was based on a two-dielectric implicit solvent model and a finite difference method
to solve the Poisson-Boltzmann equation on a cubic grid (52, 53).
Classical molecular dynamics and well-tempered metadynamics. The structure of the PDC-3
-lactamase was prepared starting from the Protein Data Bank (PDB ID 4HEF) (54) with a T79A
substitution. Nine variants (V213A, V213G, G216A, G216R, E221A, E221G, E221K, Y223A, and Y223H) were
constructed in silico using the ICM mutagenesis program (55). The system was prepared using a
high-throughput molecular dynamics (HTMD) protocol (56). Amberff14SB force field was used to define
the parameters of the protein (57), combined with explicit TIP3P water molecules (58). The systems were
minimized with 1,000 steps of steepest descent integrator and equilibrated in the NPT ensemble for 5 ns,
using a Berendsen barostat at 1 atm (59). The temperature was kept at 300 K° by a Langevin thermostat.
A 550-ns production run was carried out for all the systems in the NVT ensemble with a time step of 4
fs. All the simulations were carried out with the ACEMD program (60). To enhance sampling, Well-
Tempered Metadynamics simulations (61, 62) (WTMetaD) starting from the equilibrated structures of the
wild-type PDC-3 and variant structures were performed at 300 K using the software ACEMD and the
PLUMED 1.3 plug-in using an integration step of 4 fs. To study the flexibility of the -loop as a function
of the variants, we chose the dihedral angles of the WT/variant residue to be the collective variable (CV).
The choice of the CVs (CV1   and CV2   of the substituted residue) was based on the observation
that the slowest motions in a protein are a function of their backbone flexibility (63). Therefore, the
differences in the structural effects resulting from the changes between the wild type and the variants
should be pronounced in the backbone dihedral angles. The bias was added on the two CVs by setting
Gaussian width of 0.1 and 0.1 rad, respectively, while the Gaussian height was at 0.5 kJ/mol. Gaussians
were deposited every 4 ps, so that the deposition rate was equal to 0.125 kJ/(mol·ps). The bias factor was
fixed to 15. A total of 550 ns in the NVT ensemble were needed to reach full convergence of the free
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energy (see Fig. S2 in the supplemental material). The free energy surface of the WTMetaD simulation as
a function of the two CVs is readily obtained by integrating the deposited energy bias along the
trajectory. The error on the minima and barriers of the free energy surface was estimated from the largest
variation observed in the monodimensional projections along the collective variables during the last
100 ns of the simulation. It amounts to 0.5 kcal/mol.
The structures corresponding to the minima were selected from the WTMetaD trajectories based on
the values of the collective variables CV1 and CV2. The RMSF of the -loop was calculated from the
unbiased simulations of 1,000 ns of the WT and mutants, using the g_rmsf tool of the GROMACS 5.1.4
package (64). To remove the effect of slow, large-scale conformational transitions, the RMSF was
calculated on the C atoms in overlapping windows of 100 ns each and averaged afterwards. The first
150 ns of the simulation were considered equilibration time and omitted from the calculation. The
structural figures were generated using VMD and ICM-Pro software (55, 65, 66).
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